Skip to main content
Equibles
IDXGD logo

IDXGD · Interpace Biosciences, Inc. · Metrics

Track IDXGD — free

Use IDXGD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IDXGD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.45 +0.00 (+0.00%) At close · Sep 18
Rebalance outlook locked
Market Cap
$178.67M
Shares
27.70M

IDXGD metrics

62 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.45
Market cap
$178.67M

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
+351.0%
Price change (3M)
+286.9%
Price change (6M)
+279.4%
Price change (YTD)
+424.4%
Price change (1Y)
+686.6%
Trailing year
Price change (5Y)
—
52-week high
$7.62
52-week low
$0.82
Change from 52-week high
-15.3%
Change from 52-week low
+686.6%
Annualized volatility
450.4%
Annualized volatility (3M)
867.6%
Beta
0.6
RSI (14D)
71.4
Price vs SMA 50
+114.0%
Price vs SMA 200
+227.2%
Avg volume (3M)
5,420
Relative volume
0.2
Average dollar volume
$14,695

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
27.70M

Valuation

12 metrics
P / E (TTM)
6.4
Trailing earnings · reciprocal yield 15.7%
PEG ratio
0.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.9×
reciprocal yield 20.2%
P / book
7.7
reciprocal yield 13.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
40.1
reciprocal yield 2.5%
Earnings yield
13.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-01-20

Profitability

9 metrics
Gross margin
63.7%
Operating margin
11.5%
Trailing 12 months
Net margin
67.6%
Gross profit (TTM)
$23.04M
Operating profit (TTM)
$4.17M
Net income (TTM)
$24.45M
Trailing 12 months
Diluted EPS (TTM)
$1.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.05

Growth

11 metrics
Revenue growth YoY
-1.1%
Year over year
Net income growth YoY
+266.7%
Revenue (TTM)
$36.14M
Trailing 12 months
EPS growth YoY
+122.5%
Shares change YoY
+526.6%
Year over year · more shares
Revenue CAGR (3Y)
+89.6%
Revenue CAGR (5Y)
+3.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
105.2%
Return on assets
70.8%
Debt / equity
—
Current ratio
2.2
EBITDA (TTM)
$4.64M
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.69M
Total assets
$34.55M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.46M
Capital expenditures (TTM)
$353,000
R&D (TTM)
$594,000
SG&A (TTM)
—
Stock compensation (TTM)
$19,000
R&D / revenue
1.6%
Stock compensation / revenue
0.1%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
22 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1054102 Visit website Investor relations